Cortland Associates’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.71M Sell
5,149
-142
-3% -$79.6K 0.39% 29
2026
Q1
$2.97M Sell
5,291
-219
-4% -$140K 0.43% 27
2025
Q4
$3.73M Sell
5,510
-174
-3% -$118K 0.47% 26
2025
Q3
$3.63M Buy
5,684
+9
+0.2% +$5.46K 0.43% 28
2025
Q2
$3.04M Sell
5,675
-19
-0.3% -$9.09K 0.36% 29
2025
Q1
$2.39M Sell
5,694
-132
-2% -$57.3K 0.29% 28
2024
Q4
$2.41M Sell
5,826
-87
-1% -$38.2K 0.27% 28
2024
Q3
$2.99M Sell
5,913
-47
-0.8% -$22.8K 0.36% 25
2024
Q2
$2.9M Sell
5,960
-4
-0.1% -$2.01K 0.37% 27
2024
Q1
$3.22M Sell
5,964
-137
-2% -$74.9K 0.42% 25
2023
Q4
$3.39M Sell
6,101
-33
-0.5% -$15.5K 0.5% 25
2023
Q3
$2.68M Sell
6,134
-42
-0.7% -$20.9K 0.42% 24
2023
Q2
$3.1M Sell
6,176
-129
-2% -$61.8K 0.5% 24
2023
Q1
$3.15M Sell
6,305
-123
-2% -$58.9K 0.5% 23
2022
Q4
$2.62M Sell
6,428
-58
-0.9% -$22.5K 0.43% 23
2022
Q3
$2.11M Sell
6,486
-47
-0.7% -$17.3K 0.38% 25
2022
Q2
$2.29M Sell
6,533
-953
-13% -$389K 0.38% 26
2022
Q1
$4.09M Sell
7,486
-16,471
-69% -$8.66M 0.52% 24
2021
Q4
$15.8M Buy
23,957
+147
+0.6% +$92.3K 1.64% 20
2021
Q3
$14.8M Buy
23,810
+36
+0.2% +$24.2K 1.63% 21
2021
Q2
$15M Buy
23,774
+98
+0.4% +$54.1K 1.57% 21
2021
Q1
$11.6M Sell
23,676
-126
-0.5% -$63.1K 1.32% 21
2020
Q4
$11.9M Sell
23,802
-176
-0.7% -$78.7K 1.43% 20
2020
Q3
$9.43M Sell
23,978
-249
-1% -$92.1K 1.26% 21
2020
Q2
$8M Buy
24,227
+152
+0.6% +$44K 1.18% 21
2020
Q1
$5.83M Sell
24,075
-814
-3% -$212K 1.09% 17
2019
Q4
$6.5M Buy
24,889
+2,333
+10% +$615K 0.92% 17
2019
Q3
$6.13M Sell
22,556
-3,939
-15% -$1.1M 1.09% 16
2019
Q2
$7.29M Sell
26,495
-393
-1% -$96.8K 1.15% 16
2019
Q1
$6.01M Sell
26,888
-695
-3% -$143K 0.97% 16
2018
Q4
$5.13M Sell
27,583
-510
-2% -$105K 0.93% 16
2018
Q3
$7.01M Sell
28,093
-262
-0.9% -$63.6K 1.09% 16
2018
Q2
$6.18M Sell
28,355
-24
-0.1% -$4.95K 1% 16
2018
Q1
$5.43M Sell
28,379
-33
-0.1% -$6.09K 0.96% 16
2017
Q4
$4.44M Buy
28,412
+778
+3% +$122K 0.81% 17
2017
Q3
$4.3M Sell
27,634
-1,186
-4% -$188K 0.8% 17
2017
Q2
$4.65M Sell
28,820
-706
-2% -$115K 0.89% 15
2017
Q1
$4.57M Sell
29,526
-28,521
-49% -$3.93M 0.92% 15
2016
Q4
$6.81M Sell
58,047
-881
-1% -$101K 1.38% 16
2016
Q3
$6.64M Buy
58,928
+400
+0.7% +$42.2K 1.35% 16
2016
Q2
$5.43M Sell
58,528
-140,610
-71% -$12.1M 1.19% 17
2016
Q1
$15.6M Sell
199,138
-1,484
-0.7% -$107K 3.26% 14
2015
Q4
$14.6M Buy
200,622
+2,682
+1% +$191K 2.84% 14
2015
Q3
$14.7M Sell
197,940
-3,558
-2% -$255K 3.41% 11
2015
Q2
$12.9M Buy
201,498
+7,710
+4% +$534K 2.72% 14
2015
Q1
$15M Buy
193,788
+668
+0.3% +$52K 3.08% 14
2014
Q4
$14.3M Sell
193,120
-1,194
-0.6% -$83.7K 2.94% 15
2014
Q3
$11.4M Sell
194,314
-209,514
-52% -$13.2M 2.73% 14
2014
Q2
$27M Sell
403,828
-6,722
-2% -$427K 5.39% 7
2014
Q1
$24.9M Buy
410,550
+10,298
+3% +$614K 5.1% 7
2013
Q4
$21.3M Sell
400,252
-17,516
-4% -$922K 4.33% 10
2013
Q3
$20.8M Buy
417,768
+197,714
+90% +$9.5M 4.46% 10
2013
Q2
$9.87M Buy
+220,054
New +$9.62M 2.24% 14

Other funds holding IDXX

Cortland Associates's IDXX Position: Q2 2026 in Review

Cortland Associates reduced its Idexx Laboratories (IDXX) stake by 2.7% in Q2 2026, selling an estimated $79.6K and leaving 5,149 shares worth $2.71M. The position accounts for 0.39% of the portfolio, ranked #29.

Cortland Associates first reported a position in IDXX in Q2 2013 and has held it in 53 quarters since. The position peaked at $27M in Q2 2014. 572 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Cortland Associates held 5,149 shares of Idexx Laboratories worth $2.71M as of Q2 2026.
  • Cortland Associates sold 142 Idexx Laboratories shares in Q2 2026, an estimated $79.6K.
  • Idexx Laboratories made up 0.39% of Cortland Associates's portfolio in Q2 2026, its #29 holding.
  • Cortland Associates first reported a position in Idexx Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Cortland Associates's Idexx Laboratories position peaked at $27M in Q2 2014.
  • 572 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Cortland Associates's 13F filing for Q2 2026, filed 28 Jul 2026.